These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37214149)

  • 1. Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies.
    Thookhamme C; Navinpipat M; Sasakul A; Pattarakosol P; Lertchaisataporn K; Tawinprai K; Praditsuktavorn P
    Clin Exp Vaccine Res; 2023 Apr; 12(2):107-115. PubMed ID: 37214149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis.
    Manomaipiboon A; Phumisantiphong U; Maneerit J; Chalearmchai Y; Jirawathin W; Prajongsai A; Phankavong P; Trakarnvanich T
    Vaccine; 2022 Jan; 40(4):587-593. PubMed ID: 34969542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
    Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study.
    Porntharukchareon T; Chartisathian W; Navinpipat M; Samdaengpan C; Cheirsilpa K; Lueprasitsakul A; Worawichawong S; Muangsillapasart V; Pumuthaivirat P; Dechates B; Sirisreetreerux S; Siripongboonsitti T; Rangsrisaeneepitak V; Jirawattanapalin K; Tawinprai K
    Hum Vaccin Immunother; 2023 Aug; 19(2):2251850. PubMed ID: 37671943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study.
    Teeyapun N; Luangdilok S; Pakvisal N; Sainamthip P; Mingmalairak S; Poovorawan N; Sitthideatphaiboon P; Parinyanitikul N; Sriuranpong V; Namkanisorn T; Inthasuwan P; Angspatt P; Wongchanapat P; Bamrungnam A; Leeleakpai N; Uttha S; Jaichum S; Kongkaew P; Suksanong C; Veranitinun R; Prasomphol A; Sartsuk C; Patcharajutanon C; Preaprang S; Choengsamor H; Phongwan R; Preeyasaksa C; Phaibulvatanapong E; Suntronwong N; Yorsaeng R; Vichaiwattana P; Wanlapakorn N; Kerr SJ; Poovorawan Y; Wanchaijiraboon P; Tanasanvimon S
    EClinicalMedicine; 2022 Oct; 52():101608. PubMed ID: 35971500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
    Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
    Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
    Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
    Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers.
    Watcharananan SP; Jaru-Ampornpan P; Sahawongcharoen S; Naitook N; Himananto O; Jongkaewwattana A; Setthaudom C; Rattanasiri S; Phuphuakrat A; Thakkinstian A; Mavichak V;
    Am J Transplant; 2022 May; 22(5):1459-1466. PubMed ID: 35090091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
    Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
    Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis.
    Ling TC; Chen PL; Li NY; Ko WC; Sun CY; Chao JY; Shieh CC; Shen CF; Wu JL; Huang TC; Chao CH; Wang JR; Chang YT
    Microbiol Spectr; 2023 Feb; 11(2):e0344522. PubMed ID: 36809164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.
    Kulkarni PS; Padmapriyadarsini C; Vekemans J; Bavdekar A; Gupta M; Kulkarni P; Garg BS; Gogtay NJ; Tambe M; Lalwani S; Singh K; Munshi R; Meshram S; Selvavinayagam TS; Pandey K; Bhimarasetty DM; Ramakrishnan SR; Bhamare C; Dharmadhikari A; Vadakkedath R; Bonhomme CJ; Thakar M; Kurle SN; Kelly EJ; Gautam M; Gupta N; Panda S; Bhargava B; Shaligram U; Kapse D; Gunale B;
    EClinicalMedicine; 2021 Dec; 42():101218. PubMed ID: 34870133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.
    Valim V; Martins-Filho OA; Gouvea MDPG; Camacho LAB; Villela DAM; de Lima SMB; Azevedo AS; Neto LFP; Domingues CMAS; de Medeiros Junior NF; Moulaz IR; Dias LH; Miyamoto ST; Teixeira-Carvalho A; Mill JG;
    Front Immunol; 2022; 13():966416. PubMed ID: 36105814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
    Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.